119th Congress · introduced in the House · May 8, 2025
Access to Prescription Digital Therapeutics Act of 2025
Official title from Congress.gov
Latest action (May 8, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (May 8, 2025)
Access to Prescription Digital Therapeutics Act of 2025
This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
8 citations.
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Communi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 19, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Communi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 18, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025. Issues related to H.R. 7871/S. 1637 - MVP Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ATA ACTION · lobbying firm or registrant: BLUEBIRD STRATEGIES
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · amended · posted Jan 21, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 18, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ATA ACTION · lobbying firm or registrant: BLUEBIRD STRATEGIES
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Nov 10, 2025 · issue area: Health Issues
$10,000
Paid to lobbying firm
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 19, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADEMY OF MANAGED CARE PHARMACY · lobbying firm or registrant: TIBER CREEK GROUP
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 18, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing